Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years
Adam Ioannou(The Royal Free Hospital), Marianna Fontana(Amyloidosis Foundation), Sharmananthan Ganesananthan(MACOM (United States)), Daniel Knight(University College London), Aviva Petrie(Eastman Dental Hospital), Helen J. Lachmann(Royal Free London NHS Foundation Trust), Liza Chacko(Imperial College London), Ashutosh Wechelakar(MACOM (United States)), Gianfranco Sinagra(Società Italiana di Cardiologia), Francesco Bandera(IRCCS Policlinico San Donato), Lucia Venneri(MACOM (United States)), Philip N. Hawkins(The Royal Free Hospital), Georgina E. Williams(MACOM (United States)), James Brown(MACOM (United States)), Charlotte Manisty(National Institutes of Health), Rishi Patel(Texas Tech University), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Ambra Masi(MACOM (United States)), Carol Whelan(The Royal Free Hospital), Sophie O’Beara(MACOM (United States)), Yousuf Razvi(The Royal Free Hospital), Aldostefano Porcari(Azienda Sanitaria Universitaria Integrata di Trieste), Muhammad U. Rauf(The Royal Free Hospital), Tushar Kotecha(Royal Society), Ana Martinez–Naharro(Children's Cancer and Leukaemia Group), Paolo Massa(MACOM (United States)), James Moon(University of Michigan)
Cited by 226
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k
Truncations of Titin Causing Dilated Cardiomyopathy
|New England Journal of Medicine|2012|1.5k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k